Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00288158 · ClinicalTrials.gov registry record · Phase 2
Primary Prevention of Hypertension in Obese Adolescents
A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00288158 is a Phase 2 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 60 participants.
The verdict
NCT00288158, a Phase 2 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the consequences of lowering serum uric acid in pre-hypertensive, obese adolescents pathways involved with how uric acid mediated hypertension and renal disease. The specific aims are: 1. Test the hypothesis that lowering uric acid will improve endothelial function. 2. Test the hypothesis that lowering uric acid will reduce plasma renin activity and serum angiotensin II levels. 3. Test the hypothesis that lowering uric acid will reduce markers of inflammation
Interventions
- DRUG Placebo
- DRUG Allopurinol
- DRUG Probenecid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00288158
The ClinicalTrials.gov registry entry for NCT00288158 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00288158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00288158 about?
NCT00288158 is a clinical study titled "Primary Prevention of Hypertension in Obese Adolescents". The purpose of this study is to examine the consequences of lowering serum uric acid in pre-hypertensive, obese adolescents pathways involved with how uric acid mediated hypertension and renal disease. The specific aims are: 1. Test the hypothesis that lowering uric acid will improve endothelial fu...
What is the current status of trial NCT00288158?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2008-09. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00288158?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG), Probenecid (DRUG).
Who is sponsoring clinical trial NCT00288158?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.